TLDR
- The German biotech reported a Q4 net loss of €305 million, a sharp reversal from the €259.5 million profit recorded in the prior-year period
- 2026 revenue projections of €2–2.3 billion fell significantly short of the €2.75 billion analyst consensus
- Founding CEO Ugur Sahin and Chief Medical Officer Ozlem Tureci plan to depart by December to launch a new biotech venture
- The company will provide mRNA technology to their new startup in return for a minority ownership position and future royalties
- Declining demand for Covid-19 vaccines in the U.S. and Europe is projected to continue pressuring revenue through 2026
Shares of BioNTech experienced a brutal Tuesday morning as investors digested three pieces of troubling news at once — disappointing quarterly results, lackluster forward guidance, and the unexpected exit of the company’s founding leadership team. The stock plummeted 17% during premarket hours, tracking toward its steepest single-session decline since late 2021.
The mRNA vaccine manufacturer disclosed a fourth-quarter net loss totaling €305 million. This marked a significant deterioration from the €259.5 million profit generated during the comparable quarter last year. Quarterly revenue reached €907.4 million, representing a decline from the €1.19 billion posted previously.
On an earnings-per-share basis, the company recorded a Q4 loss of €1.25 per share. This dramatically underperformed analyst projections, which had anticipated a more modest loss of €0.45 per share.
The outlook for 2026 proved equally concerning for investors. Company leadership established revenue guidance ranging from €2 billion to €2.3 billion for the full year. This projection fell substantially below Wall Street’s consensus estimate of €2.75 billion — creating a gap of approximately €450 million when comparing midpoints.
Decreasing sales of the Comirnaty Covid-19 vaccine represent the primary factor behind the revenue shortfall. Management indicated expectations for continued weakening demand throughout both American and European markets during 2026.
Revenue from the company’s Bristol Myers Squibb cancer immunotherapy partnership is projected to remain “broadly in line with 2025,” providing minimal relief from the Covid vaccine revenue decline.
Co-Founders Set to Exit by Year-End
Adding to investor concerns was the leadership transition announcement. Company CEO Ugur Sahin alongside Chief Medical Officer Ozlem Tureci — the married couple who established BioNTech in 2008 — revealed plans to depart the organization by December 2026 to establish a new mRNA-centered biotechnology company.
The supervisory board at BioNTech has initiated a search process to identify successor leadership.
According to the announcement, BioNTech intends to provide “related rights and mRNA technologies” to the newly formed startup. In exchange, the company will receive a minority equity position, milestone-based payments, and revenue royalties. Both organizations will maintain independent operations with distinct resources and capital structures.
The husband-and-wife team transformed BioNTech into a globally recognized name throughout the Covid-19 health crisis, when their mRNA research platform enabled development of the Comirnaty vaccine in partnership with Pfizer.
mRNA Under Regulatory Pressure
Shares have also contended with an increasingly challenging regulatory environment in the United States. mRNA vaccine technology has encountered heightened examination following Robert F. Kennedy Jr.’s appointment as Secretary of Health and Human Services. The present administration has demonstrated considerable skepticism regarding mRNA vaccination platforms.
Prior to Tuesday’s sharp decline, BNTX had climbed 7.3% in 2026. Partner company Pfizer had posted gains of 7.7% during the identical timeframe.
For comparison, Moderna had surged 89% while Novavax jumped 57% entering Tuesday’s session — both substantially outperforming their larger industry competitors.
BioNTech’s projected adjusted research and development expenditures for 2026 range between €2.2 billion and €2.5 billion, demonstrating continued commitment to advancing its oncology product pipeline.
Management stated expectations to operate 15 late-stage oncology clinical programs by December, targeting transformation into a diversified multi-product organization by 2030.
BioNTech’s American depository receipts traded at $84.59 during Tuesday’s premarket session, reflecting the 17% decline.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
